Clinical Trials · NCT06348134
Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery
- Phase
- Phase 2
- Recruitment status
- Recruiting
- Sponsor
- University of Chicago
- Enrollment
- 74
- Start date
- Mar 2025
- Locations
- 4 sites, Nigeria
- Primary endpoint
- Pathological Complete Response